The short answer: funding levels changed, but the picture is more complicated than a simple cut

Federal cancer research funding did not disappear under the Trump administration, but it did shift. The National Institutes of Health (NIH), which distributes most federal cancer research money, received different budget treatment in different years between 2017 and 2021. Some cancer research programs grew while others shrank, and the total picture depends on whether you measure in raw dollars, inflation-adjusted dollars, or as a percentage of the overall NIH budget.

The clearest way to understand what happened is to look at what actually occurred rather than what was proposed. Trump's administration submitted budget proposals to Congress that would have cut NIH funding significantly in some years, but Congress did not approve those cuts. What the NIH actually received is what matters for research that actually happened.

Key Takeaways

  • The Trump administration proposed cuts to NIH funding in multiple budget proposals, but Congress rejected most of them and approved different spending levels.
  • NIH funding in inflation-adjusted dollars was lower in 2017 than it had been in 2016, but grew in subsequent years through 2021.
  • Cancer research funding specifically followed the overall NIH trend rather than being singled out for cuts or increases.
  • The National Cancer Institute, which oversees most federal cancer research, received approximately $6.5 billion annually by 2021, though this figure varies slightly year to year.

What the budget proposals actually said

In 2017, the Trump administration's first budget proposal called for cutting the NIH budget by roughly 18 percent. That proposal would have reduced the National Cancer Institute's budget from about $5.5 billion to roughly $4.5 billion. The proposal also included cuts to the Centers for Disease Control and Prevention and other health agencies.

Congress did not pass that proposal. Instead, lawmakers from both parties pushed back, and the NIH received a modest increase that year. Similar pattern played out in subsequent years: the administration proposed reductions, Congress approved different numbers, and the actual funding the NIH received reflected congressional decisions more than the administration's initial proposals.

What actually happened to NIH funding year by year

In 2017, when Trump took office, the NIH received approximately $34.1 billion in total funding. By 2021, that number had grown to approximately $42.9 billion. However, those are not inflation-adjusted figures. When you account for inflation, the 2017 budget was actually lower in real purchasing power than the 2016 budget had been under the previous administration.

The National Cancer Institute's budget followed a similar pattern. In 2016, it received approximately $5.4 billion. By 2017, that had dropped slightly to about $5.3 billion in inflation-adjusted dollars. From 2018 onward, the cancer institute's budget grew each year, reaching approximately $6.5 billion by 2021.

These figures come from the NIH's own budget documents and reports to Congress. The variation year to year is relatively small — usually less than 2 percent in either direction — and reflects both inflation and congressional appropriations decisions.

How cancer research funding compares to other NIH priorities

Cancer research is the largest single research category at the NIH, but it is not the only one. The NIH funds research into heart disease, infectious disease, neurological conditions, and dozens of other areas. The National Cancer Institute's share of the total NIH budget remained relatively stable throughout the Trump years, hovering around 15 percent of the total.

Other institutes and centers saw different treatment. The National Institute of Allergy and Infectious Diseases, which funds pandemic preparedness research, saw its budget grow significantly during this period, partly because of increased funding for HIV and hepatitis research. The National Heart, Lung, and Blood Institute saw smaller increases. The variation reflects congressional priorities more than a coordinated strategy to favor or disfavor any single disease area.

What changed in how research was conducted

Budget numbers tell only part of the story. The Trump administration also made changes to how NIH grants were reviewed and awarded. The administration emphasized "translational research" — work that moves from laboratory discovery toward actual treatments — over basic research that explores fundamental biology without an immediate application in mind.

This shift affected which research proposals were more likely to receive funding, even if the total budget remained relatively stable. Some cancer researchers reported that proposals focused on basic science were harder to fund, while those with a clear path to clinical application had better success. This is a real change in research priorities, but it is different from a budget cut.

The difference between proposed budgets and actual spending

One source of confusion is that the Trump administration's budget proposals were much more aggressive than what Congress actually approved. If you read only the proposals, it looks like cancer research funding would have been cut by billions. But proposals are not law. Congress controls the federal budget, and lawmakers chose to appropriate different amounts than the administration requested.

This is a normal part of how federal budgeting works. Every administration proposes cuts to programs it wants to reduce and increases to programs it wants to expand. Congress then negotiates and passes its own version. The actual money that flows to the NIH and the National Cancer Institute reflects the outcome of that negotiation, not the administration's opening position.

What researchers and cancer organizations said at the time

Cancer research organizations and academic medical centers had mixed reactions. Some pointed to the proposed cuts and warned that they would slow progress. Others noted that Congress had protected funding and that the actual budgets were adequate, though not generous. The American Association for Cancer Research and the American Cancer Society both testified to Congress about the importance of sustained cancer research funding during this period.

Researchers also noted that uncertainty itself was costly. When budget proposals are uncertain, institutions delay hiring decisions and long-term planning. Even if the final budget is adequate, the period of uncertainty can slow the pace of research.

Frequently Asked Questions

Did the National Cancer Institute's budget go up or down under Trump?

In raw dollars, it went up slightly from 2017 to 2021. In inflation-adjusted dollars, it dipped in 2017 compared to 2016, then grew each year after that. The overall trend from 2017 to 2021 was modest growth, though the year-to-year changes were small.

Why did Trump propose cutting cancer research if Congress didn't approve it?

Budget proposals reflect an administration's priorities and fiscal philosophy. The Trump administration proposed cuts to many domestic programs as part of a broader effort to reduce federal spending. Congress, which controls the budget, disagreed and approved different spending levels. This disagreement between the executive and legislative branches is normal.

Did cancer research funding fall behind other countries?

The United States remains the largest funder of cancer research globally, and NIH funding for cancer research is substantially larger than most other countries' total research budgets. However, comparing research spending across countries is complex because funding comes from government, private industry, and nonprofits in different proportions in different places.

How much of the NIH budget goes to cancer research?

Cancer research typically receives about 15 percent of the total NIH budget, making it the largest single disease category. The National Cancer Institute is the largest of the NIH's 27 institutes and centers.

Is cancer research funding higher or lower now than it was before 2017?

In raw dollars, it is higher. In inflation-adjusted dollars, it depends on which year you compare to. Compared to 2016, cancer research funding in 2021 was roughly equivalent when adjusted for inflation, though with year-to-year variation. Compared to earlier decades, inflation-adjusted cancer research funding has grown substantially since the 1990s.